A novel long-acting analgesic: Buprenophine palmitate in rats

Acta Anaesthesiologica Taiwanica

Volumn 43, Issue 1, 2005, Pages 11-16

  Que, Jenny ^a   Lin, Li Ching ^a   Liu, Shynn Yeu ^a   Chu, Chin Chen ^a   Liu, Kuo Sheng ^a   Ho, Shung Tai ^b   Wang, Jhi Joung ^a  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Analgesics; Buprenorphine; Esters; Long acting preparations; Pain

Indexed keywords

ANALGESIC AGENT; BUPRENORPHINE; BUPRENORPHINE PALMITATE; ESTER DERIVATIVE; LONG ACTING DRUG; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG FORMULATION; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; NONHUMAN; RAT; RAT STRAIN; RESPONSE TIME;

ANALGESICS, OPIOID; ANIMALS; BUPRENORPHINE; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAMUSCULAR; MALE; PALMITATES; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 16844373433     PISSN: 02541319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Robinson SE: Buprenorphine: an analgesic with an expanding role in the treatment of opioid addiction. CNS Drug Rev 8: 377-390, 2002.
2. Hoskin PJ, Hanks GW: Opioid agonist-antagonist drugs in-acute and chronic pain states. Drugs 30:326-344, 1991.
3. Gutstein HB, Akil H: Opioid analgesics. In: Hardman JG, Limbird LE, Goodman Gilman A, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, p569-620, 2001.
4. Tzschentke TM: Behavioral pharmacology of buprenorphine, with focus on preclinical models of reward and addiction. Psychopharmacology 161:1-16, 2002.
5. Stinchcomb AL, Dua R, Paliwal A, Woodard RW, Flynn GL: A solubility and related physicochemical property comparison of buprenorphine and its 3-alkyl esters. Pharmaceut Res 12: 1526-1529, 1995.
6. Montagne-Clavel J, Oliveras JL: The "plantar test" apparatus (Ugo Basile Biological Apparatus), a controlled infrared noxious radiant heat stimulus for precise withdrawal latency measurement in the rat, as a tool for humans? Somatosens Mot Res 13:215-223, 1996.
7. Ansel HC, Allen LV Jr, Popovich NG: Dosage from design: biopharmaceutic and pharmacokinetics considerations. In: Ansel HC, Allen LV Jr, Popovich NG, eds. Pharmaceutical dosage forms and drug delivery systems. 7th ed. Philadelphia: Lippincott Willams & Wilkins, p101-141, 1999.
8. Ansel HC, Allen LV Jr, Popovich NG: Modified-release dosage forms and drug delivery systems, in: Ansel HC, Allen LV Jr, Popovich Ng, eds. Pharmaceutical dosage forms and drug delivery systems. 7th ed. Philadelphia: Lippincott Willams & Wilkins, p229-243, 1999.
9. Ansel HC, Allen LV Jr, Popovich NG: Parenterals, In: Ansel HC, Allen Jr. LV, Popovich NG, eds. Pharmaceutical dosage forms and drug delivery systems. 7th ed. Philadelphia, Lippincott Willams & Wilkins, p397-449, 1999.
10. Beresford R, Ward A: Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drugs 33:31-49, 1987.
11. Coutinho EM, Spinola P, Barbosa I, Gatto M, Tomaz G, Morais K, Yazlle ME, Souza RN, Neto JSP, Leal WB, Leal C, Hippolito SB, Abranches AD: Multicenter, double-blind, comparative clinical study on the efficacy and acceptability of a monthly injectable contraceptive combination of 150 mg dihydroprogesterone acetophenide and 10 mg estradiol enanthate compared to a monthly injectable contraceptive combination of 90 mg dihydroxyprogesterone acetophenide and 6 mg estradiol enanthate. Contraception 55:175-181, 1997.
12. Hartgens F, Lichtenbelt WDVM, Ebbing S, Vollaard N, Rietjens G, Kuipers H: Body composition and anthropometry in bodybuilders: Regional changes due to nandrolone decanoate administration. Int J Sports Med 22:235-241, 2001.
13. Buchwald P, Bodor N: Quantitative structure-metabolism relationships: Steric and nonsteric effects in the enzymatic hydrolysis of noncongener carboxylic esters. J Med Chem 42: 5160-5168, 1999.
14. Kamischke A, Venherm S, Ploger D, Eckardstein SV, Nieschlag E: Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. J Clin Endocrinol Metab 86:303-309, 2001.
15. Imoto H, Zhou Z, Stinchcomb AL, Flynn GL: Transdermal prodrug concepts: permeation of buprenorphine and its alkyl esters through hairless mouse skin and influence of vehicles. Biol Pharm Bull 19:263-267, 1996.
16. Stinchcomb AL, Pailwal A, Dua R, Imoto H, Woodard RW, Flynn GL: Permeation of buprenorphine and its 3-alkyl ester prodrugs through human skin. Pharm Res 13:1519-1523, 1996.
17. Liu KS, Hu OY, Ho ST, Tzeng JI, Chen YW, Wang JJ: Antinociceptive effect of a novel long-acting nalbuphine preparation. Br J Anesth 92:712-715, 2004.
18. Ho ST, Wang JJ, Hu OY, Tzeng JI, Liu KS, Chen YW: The antinociceptive effect of a long-acting nalbuphine preparation in rabbits. Acta Anesthesiol Sin 41:99-103, 2003.
19. Chu KS, Wang JJ, Hu OY, Chen YW: The antinociceptive effect of nalbuphine and its long-acting esters in rats. Anesth Analg 97:806-809, 2003.
20. Chen KT, Hu OY, Ho ST, Chen YW, Wang JJ: The antinociceptive effect of nalbuphine and its long-acting prodrug, nalbuphine pivalate, in rats. Acta Anesthesiol Sin 40:191-195, 2002.